Matching articles for "PrecivityAD2"
Two New Blood Tests for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • November 23, 2026; (Issue 1768)
Two new blood tests for biomarkers that correlate with
brain amyloid beta pathology have been cleared by the
FDA to aid in the diagnosis of Alzheimer's disease (AD):
Elecsys Phospho-Tau (217P) Plasma assay...
Two new blood tests for biomarkers that correlate with
brain amyloid beta pathology have been cleared by the
FDA to aid in the diagnosis of Alzheimer's disease (AD):
Elecsys Phospho-Tau (217P) Plasma assay (Roche) and
PrecivityAD2 (C2N Diagnostics). Other FDA-cleared blood
tests for AD biomarkers are listed in Table 1. The amyloid
beta-directed antibodies lecanemab (Leqembi, and others)
and donanemab (Kisunla) are available for treatment of AD
in patients with mild cognitive impairment or mild dementia
who have confirmed brain amyloid pathology.
